Anti-doping agency to ban all gene editing in sport from 2018
By Michael Le Page,
New Scientist
| 10. 09. 2017
The battle between sports cheats and testers is poised to enter a whole new arena. The World Anti-Doping Agency has extended its 2003 ban on “gene doping” to include all forms of gene editing – but it is not clear the agency has the means to enforce this ban.
WADA already bans the use of genetically modified cells and gene therapy if they have “the potential to enhance sport performance”. From 2018, the list will also include “gene editing agents designed to alter genome sequences and/or the transcriptional or epigenetic regulation of gene expression”.
Gene editing involves tweaking existing genes, rather than adding whole new ones to a person’s body. The field is advancing incredibly fast thanks to the development in 2012 of an easy editing method called CRISPR. The first human trials of the method are already underway.
Whether people who have medical treatment involving such methods will be able to later compete in sports depends on the nature of the treatment, says WADA spokesperson Maggie Durand.
“Generally, performance enhancement implies enhancement beyond a return to normal...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...